Big Biotech a Safe Haven? AMGN Moves Higher
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Join SI Premium – FREE
Shares of Amgen (Nasdaq: AMGN) are 6% higher, helped by a Wall Street Journal piece suggesting that "big biotech" could be a good place for investors to hide this year.
The article said the perception of biotech, once considered a risky business prone to mood swings among investors, is now changing. The article says large biotech companies depend more on breakthroughs in drug technology and long-term contracts with health-care providers than on the ups and downs of the economy.
Amgen has seen its stock fall 22% over the last year due to set-backs, including studies that showed its anemia drug, Aranesp, can increase the risk of death.
Other big biotechs, Genentech (NYSE: DNA) and Genzyme (Nasdaq: GENZ), were also mentioned in the article.
Link to WSJ Artricle
The article said the perception of biotech, once considered a risky business prone to mood swings among investors, is now changing. The article says large biotech companies depend more on breakthroughs in drug technology and long-term contracts with health-care providers than on the ups and downs of the economy.
Amgen has seen its stock fall 22% over the last year due to set-backs, including studies that showed its anemia drug, Aranesp, can increase the risk of death.
Other big biotechs, Genentech (NYSE: DNA) and Genzyme (Nasdaq: GENZ), were also mentioned in the article.
Link to WSJ Artricle
You May Also Be Interested In
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- Apple Cuts Jobs in Siri, Vision Pro 3D Video and Gaming Teams - Bloomberg
- SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg
Create E-mail Alert Related Categories
Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
